Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield - Maine formulary update | …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MainePolicy N/A

    National Direct Plus Drug List (formulary)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - Maine policy alerts

    Know when Blue Cross Blue Shield - Maine releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Blue Cross Blue Shield - Maine National Direct Plus Drug List describing the three-tier prescription drug formulary, how drugs are classified, and member resources for coverage and prior authorization; it applies to members enrolled in this pharmacy benefit plan.

    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyNational Direct Plus Drug List (formulary)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionProviders can initiate prior authorization by calling Member Services or submitting the prior authorization form available on the website.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Three-TierFormulary tier structure
    QuarterlyList update frequency
    07/01/2026Effective date
    Prevention at $0Preventive drugs $0

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    150
    Document id

    Coverage Statements and Formulary Listings

    General coverage and changes

    General coverage statements and member guidance:

    The drug list shows drugs on the plan's formulary, but actual coverage depends on the member's plan design and plan documents (Certificate/Evidence of Coverage or Summary Plan Description).
    Drugs on the list are reviewed regularly and may be added, removed, or moved between tiers; the plan will notify members if a drug they take is removed or, in some cases, moved to a higher tier.
    Preventive care drugs are covered with zero cost share in compliance with the Affordable Care Act (ACA).

    Utilization management

    Utilization management and exceptions:

    Utilization controls such as prior authorization (PA), step therapy (ST), age limits (AL), quantity limits (QL), limited distribution (LD), specialty designation (SP), and other plan notes may apply as indicated in the Notes column of the drug list.
    Providers may request prior authorization or a coverage review (preapproval) by calling the Member Services number on the back of the member ID card or by submitting the prior authorization form available on the plan website.
    For contraceptives not on the formulary, prescribers may request a medical exception; when medically necessary, cost share may be waived per the plan's exception process.

    Formulary tier and utilization management indicators

    Formulary tiers and numeric designations appear for drugs; some entries include utilization management notes (e.g., PA).

    The drug list uses a three-tier structure (Tiers 1/1a/1b, 2, 3) to indicate member cost share; specific tier designations are shown adjacent to drug entries.
    Plan note abbreviations shown on the list include PA (prior authorization), QL (quantity limits), DO (dose optimization), LD (limited distribution), SP (specialty), BE (benefit exclusion/bioequivalent), ST (step therapy), and AL (age/abuse limit).

    Selected coverage entries (examples from this window)

    Coverage stance is expressed as Tier assignments plus notes. Examples from the extract:

    guanfacine hcl er oral tablet (extended release) — Tier 1 or 1b with Notes: PA.
    Various amphetamine/dextroamphetamine ER formulations — Tier 1 or 1b; Notes indicate PA and either QL or DO depending on strength.
    lisdexamfetamine dimesylate (higher strengths) — Tier 1 or 1b with Notes: PA; QL.
    WEGOVY (subcutaneous solution pen-injector) — listed with tier and Notes including PA; BE; QL (example of anorexiant listing in extract).
    SUNOSI oral tablet (75-150 mg) — Tier 3 with Notes: PA; DO or QL as indicated.
    ARIKAYCE inhalation suspension — listed with Notes: LD; QL (limited distribution and quantity-limit notation for certain formulations).

    Partial coverage listing and annotations

    Selected coverage stance and restrictions by product/class as shown in the list:

    COX-2 inhibitors and common NSAIDs (e.g., celecoxib, diclofenac, ibuprofen, naproxen, ketorolac, meloxicam, etodolac) — many oral formulations listed at Tier 1 or 1a/1b with Notes indicating QL for certain strengths or formulations; some IV formulations may show QL without tier assignment in the excerpt.
    IL-1 / IL-1B blockers (examples: Arcalyst, Ilaris) — entries show utilization controls such as PA; LD; QL; SP in this extract.
    PDE4 inhibitor Otezla — listed with Notes indicating PA; QL; SP (example of a Tier 3 specialty product with prior authorization and quantity limits).
    Biologic DMARDs (examples: Orencia, Enbrel, Enbrel cartridge/prefilled presentations) — some presentations listed as Tier 3 with Notes: PA; QL; SP for certain prefilled syringes/cartridges.
    Opioids (codeine combinations, hydrocodone combinations, fentanyl, morphine, methadone, oxycodone, etc.) — various tier assignments; many entries include QL, PA, and AL notations; select formulations listed as Tier 3.

    Coverage stance in excerpt

    The excerpt lists drugs with assigned tier numbers and utilization controls; where present products are marked with PA (prior authorization), QL (quantity limits), LD (limited distribution) or tier designations (1, 1b, 2, 3). No full coverage criteria or step therapy algorithms are included in this section.

    Methadone (oral: concentrate, solution, tablet) — listed with Notes: PA; QL for multiple oral formulations in the extract.
    Multiple opioid combination products and tramadol ER entries — Notes indicate PA and/or QL requirements for combinations and extended-release formulations.
    Testosterone products (transdermal gels and other formulations) — entries show Notes: PA; QL and Tier 1 or 1b designations for many strengths in the excerpt.
    Overall coverage stance in this excerpt is 'covered with criteria' — members should consult plan documents and the full formulary for complete prior authorization criteria and quantity limits, which are not fully present in this extract.

    Formulary Codes, Annotations, and Notes

    Formulary notes / abbreviationsmixed
    PAPrior authorization required
    STStep therapy required
    QLQuantity limits
    ALAge limits
    BEBenefit exclusion
    DODose optimization
    LDLimited distribution
    SPSpecialty drugs
    $0Preventive drugs with $0 cost share
    No codes in this sectionmixed
    No codes listed
    No coding listed in TOCmixed
    No codes listed
    No codes in this segmentmixed
    No codes listed
    No codes in this sectionmixed
    No clinical codes (CPT/HCPCS/ICD-10/NDC) are present in these chunks; content is heading/table of contents text.
    Codes not presentmixed
    No billing or diagnostic codes present in this excerpt; only drug class headings and page references.
    No billing or coding entries in this fragmentmixed
    Drug categories (TOC)mixed
    No codes listed
    No codes in contentsmixed
    No billing or clinical codes listed in this section (table of contents).
    No billing or drug codes in this fragmentmixed
    No codes listed
    Formulary note codesmixed
    PAPrior Authorization required (observed in Notes fields)
    QLQuantity Limits
    DODispense/Day/Other plan-specific note (observed abbreviation)
    LDLimited Distribution
    SPSpecialty designation
    BEBioequivalent or brand-exclusion note
    STStep Therapy
    Formulary annotations and cost/share flagsmixed
    $0Cost share designation shown for many low-dose aspirin and some OTC equivalents
    PAPrior authorization
    QLQuantity limit
    SPSpecialty
    LDLimited distribution
    ALAbuse/age limit or alert (context shows AL applied to some opioid/codeine products)
    Codes not listed in excerptmixed
    No explicit NDC/CPT/HCPCS codes present in these chunks; only product names, tiers, and utilization controls.
    Document completeness
    CompletenessPartial — multiple Table of Contents fragments are repeated across pages; this extraction does not include full drug-specific coverage criteria.
    Effective date in excerptEffective 07/01/2026 shown on list
    Document partPartial TOC excerpts and repeated page references (multiple chunks), not a complete formulary document
    No thresholds defined

    Prior Authorization, Coverage Reviews, and Provider Guidance

    Prior Authorization

    Initiate PA or ST via Member Services or form

    Notes column indicates if prior authorization (PA) or step therapy (ST) is required; providers can initiate prior authorization by calling the Member Services number on the back of the member ID card or by downloading and submitting a prior authorization form from the website.

    Prior Authorization

    Request coverage review for non‑formulary drugs

    If a drug is not on the drug list, the prescriber can request a coverage review (preapproval/prior authorization) by calling the Member Services number on the back of the member ID card or by downloading and submitting a prior authorization form from the website; members may have to pay full cost if not covered until approval is granted.

    • Coverage review initiated by prescriber via Member Services phone number or prior authorization form
    • If approved, patient cost depends on the plan's benefit

    Definitions and Formulary Structure

    Drug list / formulary
    DefinitionFormulary (drug list): a list of prescription medicines the plan covers, including FDA-approved brand-name and generic drugs.
    ScopeIncludes hundreds of brand-name and generic drugs; coverage depends on member's specific plan design and benefit documents.
    Document roleProvides member-facing index (TOC) and drug entries with tier and utilization annotations; full coverage rules located elsewhere in plan materials.
    Tiers
    Tier structureThree-Tier structure: Tier 1 (lowest cost share; may be split to 1a/1b), Tier 2 (higher cost share; preferred brands/newer generics), Tier 3 (highest cost share; non-preferred or specialty).
    Tier 1a/1b noteSome plans include Tier 1a and 1b distinctions; refer to the member's pharmacy benefit summary for specifics.
    Policy Summary
    PayerBlue Cross Blue Shield - Maine
    PolicyNational Direct Plus Drug List (formulary)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionProviders can initiate prior authorization by calling Member Services or submitting the prior authorization form available on the website.
    SourceLink
    On This Page
    Coverage Statements and Formulary ListingsFormulary Codes, Annotations, and NotesPrior Authorization, Coverage Reviews, and Provider GuidanceDefinitions and Formulary Structure
    HUMIRA (various presentations) — Tier 3 with Notes: PA; QL; SP (prior authorization, quantity limit, specialty).
    Aspirin and low-dose salicylate OTC equivalents — multiple low-dose aspirin products shown with $0 cost share and Tier 1 or 1a designations in the excerpt.
    Note: This excerpt does not include complete prior authorization criteria, step-therapy algorithms, or full clinical requirements — only tier and Notes annotations present in these chunks.
    Defined numeric thresholdsNo explicit numeric thresholds (e.g., mg/day limits or specific quantity/dispense counts) are defined in the extracted segments.
    Notes column useUtilization annotations (PA, QL, ST, etc.) are present but without numeric QL values in this excerpt.
    Where thresholds appearWhen present, quantity/strength-specific controls are shown adjacent to particular strengths/formulations (see full formulary for details).
    Quantity limits / dose-based notes
    Dose/strength-specific QL or PACertain extended-release stimulant strengths list PA or QL by strength (e.g., amphetamine-dextroamphetamine ER: some strengths Notes = PA; QL).
    LisdexamfetamineHigher strengths (40–70 mg) are noted with PA; QL for some strengths and DO for others.
    Formulation-specific controlsNotes vary by formulation (ER, tablet, solution) with QL/PA applied to specific presentations rather than a blanket rule.
    Quantity limits and tiering
    Preferred-tier QLMany NSAID and analgesic formulations are assigned Tier 1 or 1a/1b with Notes = QL, indicating quantity limits apply even to preferred-tier products.
    IV and ER formulationsSome IV or extended‑release presentations show QL separately from oral tablet tiers; tiers may be blank while QL is shown.
    Tiering plus QLTier assignment and quantity limits are displayed together per presentation (tier may be 1/1a/1b, 2, or 3 with QL noted where applicable).
    Quantity limits and prior auth flags
    PA + QL co-occurrenceMultiple opioid combination entries list both PA and QL in the Notes column (e.g., oxycodone-acetaminophen combos show Notes = QL; opioids overall show PA; QL).
    Methadone entriesMethadone oral presentations are specifically shown with PA; QL noted for concentrate, solution, and tablet forms.
    Tramadol and combinationsSeveral combination opioids and tramadol ER entries indicate PA and/or QL requirements (no numeric limits provided in excerpt).
    Prior Authorization

    Request medical exception for contraceptives

    If the contraceptive a member is taking is not on the formulary, the prescriber may contact the plan to request coverage when medically necessary; the plan will waive the member's cost share if preferred contraceptives are inappropriate.

    Note

    TOC entries — categories only (no PA rules)

    Table of contents entries list drug categories and page references for the National Direct Plus Drug List; these TOC fragments do not include prior authorization rules or coverage criteria.

    Note

    TOC: therapeutic categories (navigation only)

    Therapeutic category headings (e.g., Antifungals; Antihistamines; Antihyperlipidemics; Antihypertensives) are provided in the Table of Contents as navigation only; they do not contain authorization instructions in these excerpts.

    Note

    TOC fragment — no authorization info

    This Table of Contents fragment contains only section headings and page numbers and does not describe prior authorization or provider actions.

    Note

    TOC listing of drug classes (partial)

    Table of Contents lines list drug classes and page numbers for the National Direct Plus Drug List; no provider action guidance appears in this partial TOC.

    Note

    TOC fragment — no PA guidance

    This TOC fragment contains section headings only and does not include prior authorization or provider action guidance.

    Note

    TOC: class headings (navigation)

    Table of Contents entries name drug classes (e.g., Beta Blockers; Calcium Channel Blockers; Contraceptives; Corticosteroids) and page references; these entries are for navigation and do not include authorization instructions in this segment.

    Note

    TOC: additional therapeutic categories

    Table of contents lists therapeutic categories (e.g., Cough/Cold/Allergy; Dermatologicals; Endocrine and Metabolic Agents) as section headings; no authorization steps are described here.

    Note

    TOC segment — navigation headings

    This TOC segment lists endocrine, fluoroquinolones, gastrointestinal, anesthetic, and genitourinary categories among others for document navigation; it does not present PA criteria in the excerpt.

    Note

    TOC fragments — no PA guidance

    Table of contents pages in this window are navigation-only and contain no prior authorization guidance.

    Note

    TOC: drug categories (index entries)

    Table of Contents lists drug categories and page references for the National Direct Plus Drug List; these fragments are index headings and do not include provider action language in the excerpt.

    Prior Authorization

    Watch for 'PA' indicator in tier listings

    Some drug list entries include 'PA' in the Notes column indicating prior authorization is required for that product (example: guanfacine ER shows 'PA' adjacent to its listing).

    Documentation Required

    Check Notes column for utilization controls

    Many product listings include plan note abbreviations that indicate utilization management controls (PA = prior authorization, QL = quantity limits, DO/LD/SP/BE/ST are plan-specific notes); providers should check the Notes column on the drug list for applicable controls.

    • PA = Prior Authorization
    • QL = Quantity Limit
    • ST = Step Therapy
    • LD = Limited Distribution
    • SP = Specialty
    Prior Authorization

    Follow utilization-control annotations (PA/QL/SP/LD)

    Certain products in the list are annotated with utilization-control abbreviations next to the drug entry (e.g., PA, QL, SP, LD); providers should follow those controls when prescribing and dispensing.

    Prior Authorization

    Otezla requires PA, QL, and specialty handling

    Otezla and related therapy packs are listed with Notes = PA; QL; SP, so prior authorization, quantity limits, and specialty handling apply to these PDE4 inhibitor products.

    Denial Risk

    Opioid entries commonly have PA, QL, and AL

    Multiple opioid products are listed with annotations such as AL (age/abuse limit), PA, and QL; prescribing or dispensing opioids without following these controls risks denial or coverage limitation.

    • Some opioid formulations (e.g., fentanyl patch) show 'PA; QL' next to the entry
    • Age/abuse limits (AL) may apply to certain codeine products
    Prior Authorization

    Methadone oral forms require PA and QL

    Methadone oral formulations are shown with Notes = PA; QL, indicating prior authorization and quantity limits apply to methadone HCl oral concentrate, solution, and tablet.

    Billing Rule

    Combination opioids and tramadol may need PA and QL

    Several opioid combination products and tramadol ER entries include Notes indicating PA and/or QL requirements; providers should obtain any required prior authorization and adhere to quantity limits to avoid claim denials.

    Prior Authorization

    Testosterone products require PA and QL (some LD)

    Multiple testosterone products (transdermal gels and other presentations) are listed with Notes = PA; QL (and some flagged as LD), so prior authorization and quantity limits apply when prescribing androgen/testosterone therapies.

    Cost share guidanceLower tiers correspond to lower member cost share; tier placement is based on clinical value, OTC availability, and cost comparisons.
    P&T process
    P&T committeeDrugs are reviewed by a Pharmacy & Therapeutics (P&T) committee composed of independent physicians, pharmacists and other clinicians who recommend formulary placement based on safety, efficacy and value.
    Review frequencyThe P&T group meets regularly to evaluate new and existing drugs for inclusion or tier changes.
    Decision basisRecommendations consider clinical effectiveness, safety, and cost/value to members and the plan.
    TOC entries
    TOC purposeLists therapeutic categories and page references for the National Direct Plus Drug List (e.g., Allergenic Extracts/Biologicals, Aminoglycosides).
    NavigationTOC entries help locate drug classes and specific product listings within the formulary document.
    Partial coverageThe extracted TOC fragments are partial and repeated across pages in this excerpt.
    Table of Contents
    TOC fragmentsMultiple Table of Contents fragments are presented showing therapeutic classes (e.g., Antifungals; Antihistamines; Antihyperlipidemics).
    Page referencesTOC entries include page numbers or placeholders that guide readers to sections (several pages referenced across fragments).
    RepetitionTOC content is repeated across chunks in the document extraction window.
    TOC entries
    TOC scopeIncludes broad therapeutic categories (e.g., Antihypertensives, Anti-infective Agents - Misc., Antimalarials, Antineoplastics).
    OrganizationCategories are grouped and shown with section headings and page references; useful for locating drug class listings.
    No authorization rulesTOC fragments contain headings only; specific prior authorization rules are not described in the TOC itself.
    Table of Contents entries
    Therapeutic headingsTOC includes headings such as Antipsychotics/Antimanic Agents, Antiseptics & Disinfectants, Antivirals, Beta Blockers.
    IndexingEntries in the TOC map broad drug classes to pages where individual products and tier/notes appear.
    Partial extractThis is a partial TOC segment of the full formulary document.
    Table of Contents fragments
    Contraceptives in TOCContraceptives are listed as a TOC category (with page reference), indicating a dedicated section in the drug list.
    Multiple cardiac classesTOC also lists cardiovascular-related classes (Beta Blockers, Calcium Channel Blockers, Cardiotonics, Cephalosporins).
    No PA detail in TOCTOC does not provide prior authorization or utilization management rules—those appear with drug entries.
    TOC (partial)
    Indexing detailTOC spans many pages and sections (numerous page references shown); the extract contains repeated TOC lines across chunks.
    ExamplesTOC entries include Corticosteroids; Cough/Cold/Allergy; Dermatologicals; Diagnostic Products; Digestive Aids.
    Partial onlyExtracted TOC lines do not represent the complete document index.
    Table of contents entries
    Repeated class listingsTOC repeats classes such as Dermatologicals, Diagnostic Products, Digestive Aids, Diuretics, Endocrine & Metabolic Agents.
    Page guidanceEntries include page ranges (e.g., ~77–96 across fragments) to aid navigation.
    Incomplete extractThese are TOC excerpts; full section content and rules are in the main formulary pages.
    Table of Contents (partial)
    General TOC segmentTOC lists Endocrine & Metabolic Agents - Misc., Fluoroquinolones, Gastrointestinal Agents - Misc., General Anesthetics, Genitourinary Agents - Misc.
    Page placeholdersSeveral entries and page placeholders are duplicated across chunks, consistent with partial extraction.
    Navigation noteRefer to the full formulary document for complete section contents and utilization requirements.
    Table of Contents
    Gout/Hematology/HemostaticsTOC shows Gout Agents, Hematological Agents - Misc., Hematopoietic Agents, Hemostatics, Hypnotics/Sedatives/Sleep Disorder Agents as separate sections.
    Structured indexThe TOC provides a structured index across many therapeutic areas to locate drug listings and notes.
    Partial extract cautionTOC entries do not include the detailed utilization rules — see product entries for PA/QL specifics.
    Table of Contents (TOC)
    Formulary typeThree-tier formulary structure is used for this drug list.
    Effective date shownCurrent as of 7/1/2026 on the extracted pages.
    Tier mappingDrug entries show tier (1/1a/1b, 2, 3) alongside Notes fields for utilization controls.
    Three-tier formulary
    Three-tier explanationThe plan uses a three-tier structure and may include Tier 1a/1b distinctions; members should refer to their pharmacy benefit summary for plan-specific tiering.
    Member guidanceLower tiers mean lower member cost share; tier placement considers clinical value, OTC options, and cost.
    Refer to benefit materialsTier labels in the drug list should be interpreted with the member's Certificate/Evidence of Coverage or pharmacy benefit summary.
    Tier 1a/1b
    Tier 1a/1b meaningTier 1a and 1b are sub‑levels within Tier 1 used by some plans to indicate the lowest cost share (1a) versus a slightly higher generic tier (1b).
    Plan-specificInclusion of 1a/1b varies by plan; members should check their specific plan documents for cost-share distinctions.
    Displayed in entriesDrug entries in the list may show Tier = 1 or 1b or 1a as applicable per presentation.
    Plan note abbreviations
    PAPrior Authorization required (annotation 'PA' observed in Notes fields).
    QLQuantity Limit (annotation 'QL' observed next to many product presentations).
    Other abbreviationsDO (dispense/dose optimization), LD (limited distribution), SP (specialty), BE (bioequivalent/benefit exclusion), ST (step therapy) also appear in Notes.
    Formulary annotation shorthand
    PA = Prior authorizationPA indicates a prior authorization requirement for the listed product or presentation.
    QL = Quantity limitQL denotes that quantity limits apply to the specific formulation/strength.
    SP/LD/AL/$0SP = specialty designation; LD = limited distribution; AL = abuse/age alert; $0 = zero patient cost share for specified preventive products.
    PA (prior authorization)
    PA (definition)PA = Prior authorization; plan requires prescriber to request approval before coverage is provided for the listed product.
    How to requestProviders can initiate prior authorization via Member Services phone or a prior authorization form as described elsewhere in the formulary materials.
    Where shownPA appears in the Notes column adjacent to specific drug presentations in the drug list.
    QL (quantity limit)
    QL (definition)QL = Quantity limit; indicates limits on the amount of medication dispensed over a defined time period for the specific presentation.
    Presentation-specificQL annotations are applied to specific strengths and formulations (e.g., ER tablets, IV solutions) rather than universally across a drug class.
    No numeric QL in excerptThis extraction shows QL flags but does not include numeric quantity limits; refer to full formulary rules for exact limits.